The Lancet paper: Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-rand

The Lancet paper: Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31866-3/fulltext https://www.thelancet.com/journals/lancet/article/PIIS0140-6...